Short-term effects of different doses of dexamethasone on fetal biophysical activities and Doppler flow velocity parameters: a randomized controlled trial substudy

开始日期2024-10-15

申办/合作机构

Navamindradhiraj University

[+1]

TCTR20240924006 / Recruiting临床2/3期IIT

Efficacy and safety of oral N-acetylcysteine in prevention of post embolization syndrome

开始日期2024-08-05

申办/合作机构

Faculty of Medicine Siriraj Hospital

100 项与 Faculty of Medicine Siriraj Hospital 相关的临床结果

登录后查看更多信息

0 项与 Faculty of Medicine Siriraj Hospital 相关的专利（医药）

登录后查看更多信息

178

项与 Faculty of Medicine Siriraj Hospital 相关的文献（医药）

2024-09-13·BMJ case reports

Differential diagnosis of pseudogout of the lumbar spine.

Article

作者: Suvithayasiri, Siravich ; Kanjanakeereewong, Ishthayapong ; Tirawanish, Panlop ; Ruangchainikom, Monchai

This case report details a rare instance of calcium pyrophosphate dihydrate crystal deposition disease (CPPD), commonly known as pseudogout, affecting the lumbar spine. A man in his mid-50s of age presented with severe low-back pain and fever, initially suspected as a spinal infection. Elevated erythrocyte sedimentation rate and leucocytosis were observed, while the initial imaging showed only lumbar spondylosis with arthritic changes in the right L4-L5 facet joint. However, an MRI revealed a cystic lesion at the right L5-S1 facet joint without signs of spondylodiscitis. Ultrasound-guided needle aspiration and synovial fluid analysis, including polarised light microscopy, identified calcium pyrophosphate crystals. Treatment with intravenous pain management was initially ineffective. Confirmation of CPPD led to successful treatment with oral colchicine, resulting in rapid pain alleviation and fever reduction. The patient reported significant improvement at a 2-week follow-up. This case emphasises the importance of thorough investigation in differentiating common symptoms and avoiding unnecessary treatments, highlighting the role of histological examination in diagnosing rare conditions like spinal CPPD.

2024-08-10·Journal of Clinical Oncology

COVID-19 infection impact on race and clinical outcome of patients with breast cancer: A nationwide analysis.

作者: Suenghataiphorn, Thanathip ; Kansuttiviwat, Chalermkiat ; Saowapa, Sakditad ; Lohawatcharagul, Tuntanut ; Kulthamrongsri, Narathorn

16 Background: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide. Recent data showed the detrimental effects of COVID-19 infection on other neoplasm conditions, causing increased mortality rates and complications. However, limited information exists on the specific impacts of COVID-19 infection in patients hospitalized for breast cancer, as well as racial impact differences. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to investigate the effects of COVID-19 infection on cases primarily admitted due to breast cancers. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was inpatient mortality, with secondary outcomes including system-based complications. Statistical significance was established at a p-value of 0.05. Results: We identified 25,559 patients with a primary discharge diagnosis of breast cancer. The mean age was 59.7 years; 99.28% were female. In the non-COVID group, Caucasians accounted for 60%, followed by African Americans (19%). However, in the COVID-19 group, African Americans predominated with 41%, followed by Caucasian (35%) (p-value = 0.05). Of these, 0.52% (85/25,559) had a concurrent diagnosis of COVID-19 infection. In a survey multivariable logistic and linear regression model adjusting for patient and hospital factors, COVID-19 infection was associated with higher in-hospital mortality (aOR 6.07; 95% CI (1.26, 29.13), p = 0.024), higher mean length of stay(b 5.22; 95% CI (2.08,8.36) p =0.001), acute respiratory failure (aOR 4.88; 95% CI (1.51, 15.77), p = 0.008), coagulopathy (aOR 8.38; 95% CI (2.19, 32.02), p=0.002) and SIRS (aOR 6.38; 95% CI (1.25, 32.50), p = 0.026). We observed non-significant, but increased, risks of acute kidney injury (AKI), shock, and sepsis, as well as total hospitalization costs in COVID-19-positive patients. Conclusions: In conclusion, our study underscores that COVID-19 infection is associated with higher in-hospital mortality and other clinical outcomes in breast cancer patients, as well as, a disproportionated impact against some races. Future longitudinal studies are warranted to comprehensively assess the causation of these clinical outcomes in this population.

2024-08-10·Journal of Clinical Oncology

Clinical outcome of patients hospitalized for pancreatic-biliary malignancy with comorbid acute decompensated heart failure: An analysis from National Inpatient Sample (NIS).

作者: Suenghataiphorn, Thanathip ; Thongpiya, Jerapas ; Kulthamrongsri, Narathorn ; Danpanichkul, Pojsakorn ; Chaisidhivej, Natapat ; Lohawatcharagul, Tuntanut ; Kansuttiviwat, Chalermkiat ; Saowapa, Sakditad ; Wattanachayakul, Phuuwadith

81 Background: Recent data suggest an association between cardiovascular disease burden and biliary cancer patients. However, the outcomes of hospitalized patients for biliary-pancreatic malignancy with concurrent acute decompensated heart failure (ADHF) are not well understood. Therefore, our objective is to assess the impact of ADHF on patients hospitalized for biliary-pancreatic malignancy. Methods: We used the 2020 U.S. National Inpatient Sample (NIS) to study patients hospitalized for biliary tract and pancreatic malignancy with concurrent acute decompensated heart failure (ADHF) identified by ICD-10 CM codes. Adjusted odds ratios (aORs) for predefined outcomes were determined via multivariable logistic and linear regression analyses. The primary outcome examined was inpatient mortality, while secondary outcomes included complications related to various body systems. Results: We identified 43,009 patients with a primary discharge diagnosis of biliary tract and pancreatic cancer. The mean age was 68.5 years; 49.4% were female. Caucasians accounted for 68%, followed by Hispanics (13%). Of these, 6.27% (3,699/43,009) had a concurrent diagnosis of heart failure. In the survey's multivariable logistic and linear regression analysis, accounting for patient and hospital confounding factors, ADHF demonstrated significant associations with higher in-hospital mortality (aOR 1.63; 95% CI 1.09, 2.44, p = 0.015). In addition, a significant association between ADHF and various adverse in-hospital outcome was observed including prolonged mean length of stay (Beta 1.45; 95% CI 0.67, 2.24, p < 0.001), increased mean total hospital cost (Beta 3,757; 95% CI: 2,641, 36,630, p = 0.024), elevated risk of shock (aOR 2.75; 95% CI: 1.77, 4.26, p < 0.001), higher risk of sepsis (aOR 1.71, 95% CI: 1.09, 2.68, p = 0.018), increased risk of acute respiratory failure (aOR 3.18, 95% CI: 2.25, 4.51, p < 0.001), and heightened risk of acute kidney injury (aOR 1.57; 95% CI: 1.24, 1.99, p < 0.001). Conclusions: Among patients hospitalized for biliary-pancreatic malignancy, concurrent ADHF is linked to increased mortality risk and various in-hospital adverse complications. Additional long-term studies are required for a comprehensive understanding of this association.

项与 Faculty of Medicine Siriraj Hospital 相关的新闻（医药）

2020-12-07

·Healthcare IT News

Huawei & Siriraj Hospital sign MoU to establish 5G powered smart platform for medical services

Huawei Technologies (Thailand) Co. Ltd. and the Faculty of Medicine, Siriraj Hospital, under Mahidol University, has signed the 5G Powered Smart Hospital Enabled with Cloud and AI Memorandum of Understanding (MoU) to establish a smart platform that will enhance innovative medical services. This MoU comes in response to the Faculty of Medicine Siriraj Hospital's mission to serve better by becoming a smart center that will apply integrated digital technologies using 5G infrastructure, artificial intelligence (AI), big data and cloud edge computing, in order to offer enhanced services. WHAT’S IT ABOUT Under the five-year agreement, Huawei will provide 5G technology to the Faculty, enabling the immediate upgrade of the existing infrastructure. It will also share knowledge and collaborate with Siriraj researchers and academic staff to enable Siriraj to operate more efficiently. Both parties will work together in other jointly-developed projects that may arise in the course of the MoU. Siriraj will participate with Huawei for further 5G ecosystem partnership cooperation to promote 5G technology and innovations, in the form of demonstration events and exhibitions. The hospital will also work with Huawei for joint academic sessions, to arrange training classes or technology sharing opportunities, and to study the latest technology topics including, but not limited to, 5G, AI and Cloud. THE LARGER TREND Siriraj Hospital, which is Thailand’s largest government hospital, is the first hospital in Southeast Asia to deploy two NVIDIA DGX A100 systems for medical research and clinical applications, Healthcare IT News reported. In South Korea, KT, the country’s largest telecommunications company and Samsung Medical Center are jointly developing a 5G-powered medical service as an initial step to establishing a 5G smart hospital. The two partners have been applying 5G on site to create better medical services since they signed a MoU in September 2019. ON THE RECORD “It is an honor for Faculty of Medicine Siriraj Hospital to partner with Huawei for this MoU that will raise the level and standards of our services and improve operational efficiency. This marks the initial step to establishing Thailand's first 5G smart state hospital,” said Prof. Dr. Prasit Watanapa, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University. “The healthcare sector can benefit immensely from smart innovations and infrastructure during this era of digitalization. We would like to accompany Thailand as it develops a strong, connected healthcare ecosystem in order to increase healthcare penetration in rural and remote communities and improve the quality of life of the people,” said Abel Deng, CEO of Huawei Technologies (Thailand).

100 项与 Faculty of Medicine Siriraj Hospital 相关的药物交易

登录后查看更多信息

100 项与 Faculty of Medicine Siriraj Hospital 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CD19 CAR-T (Faculty of Medicine Siriraj Hospital) ( CD19 )	非霍奇金淋巴瘤更多	临床1期
VP-001 (PYC Therapeutics) ( CNOT3 x PRPF31 )	视网膜色素变性11型更多	临床前